{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054442","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.365562+00:00","generated_at":"2026-06-02T18:45:48.654470+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M","bullets":["STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.","Suspended all mavodelpar development; reduced workforce by ~90% in Dec 2023 and Feb 2024.","Retained independent financial advisor to explore strategic alternatives, including possible sale.","Q1 2024 net loss $8.4M ($0.25/share) vs $15.1M ($0.60/share) Q1 2023; cash $82.8M as of Mar 31, 2024.","R&D expenses fell to $4.9M from $11.0M due to program suspension and cost-cutting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054442","json":"https://secwatch.observer/filing/0000950170-24-054442.json","markdown":"https://secwatch.observer/filing/0000950170-24-054442.md","text":"https://secwatch.observer/filing/0000950170-24-054442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/rphm-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:45:48.654470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa9fbaf5bed2bf9df4317acc97cf2333725f806e","claim":"OnKure Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $8.4 million, or $0.25 per share, EPS $0.25 per share.","evidence_excerpt":"We reported a net loss of $8.4 million, or $0.25 per share, during the first quarter of 2024, compared to a net loss of $15.1 million, or $0.60 per share, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $8.4 million, or $0.25 per share"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}